Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
University of Heidelberg H. W. & J. Hector-Stiftung, Weinheim Faculty of Medicine, University of Heidelberg Dafra Pharma Research & Development BVBA |
---|---|
Information provided by: | University of Heidelberg |
ClinicalTrials.gov Identifier: | NCT00764036 |
The purpose of this study is the evaluation of the tolerability of an add-on therapy with artesunate with a duration of 4 weeks in patients with advanced cancer.
Condition | Intervention | Phase |
---|---|---|
Metastatic Breast Cancer Locally Advanced Breast Cancer |
Drug: artesunate |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
Official Title: | Prospective Open Uncontrolled Phase I Study of Compatibility, Safety&Pharmacokinetics of Artesunate, a Semisynthetic Derivative of Artemisinin From the Chinese Herb Artemisia Annua in Patients With Metastatic/Locally Advanced Breast Cancer |
Estimated Enrollment: | 18 |
Study Start Date: | October 2008 |
Estimated Study Completion Date: | September 2011 |
Estimated Primary Completion Date: | September 2010 (Final data collection date for primary outcome measure) |
Additional objectives are
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Cornelia U v. Hagens, MD | 00496221-56 ext 8321 | cornelia.von.hagens@med.uni-heidelberg.de |
Contact: Julia E Osburg, MD | 00496221-56 ext 8312 | julia.osburg @med.uni-heidelberg.de |
Germany, Baden-Württemberg | |
Complementary and Integrative Medicine, Dep. Gyn. Endocrinology, Women's Hospital, University of Heidelberg | Recruiting |
Heidelberg, Baden-Württemberg, Germany, D-69115 | |
Contact: Andrea Mallok, SN 0049-6221-56 ext 8321 andrea.mallok@med.uni-heidelberg.de | |
Sub-Investigator: Anita Glenz, MD |
Principal Investigator: | Cornelia U v. Hagens, MD | Department of Gynecological Endocrinology and Reproductive Medicine |
Responsible Party: | Complementary&Integrative Med., Dep. 4.2, University Women's Hospital Heidelberg ( Dr. med. Cornelia von Hagens ) |
Study ID Numbers: | M33/2, EUDRACT 2007-004432-23 |
Study First Received: | September 30, 2008 |
Last Updated: | November 19, 2008 |
ClinicalTrials.gov Identifier: | NCT00764036 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
phase I safety |
Artesunate Artemisinins Skin Diseases Artemisinine |
Breast Neoplasms Dihydroquinghaosu Marijuana Abuse Breast Diseases |
Anti-Infective Agents Antimalarials Antiparasitic Agents Antiprotozoal Agents Neoplasms |
Neoplasms by Site Therapeutic Uses Amebicides Pharmacologic Actions |